A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis

Walker, B.A. (Brian A.); Mavrommatis, K. (Konstantinos); Wardell, C.P. (Christopher P.); Ashby, T.C. (T. Cody); Bauer, M. (Michael); Davies, F. (Faith); Rosenthal, A. (Adam); Wang, H. (Hongwei); Qu, P. (Pingping); Hoering, A. (Antje); Samur, M. (Mehmet); Towfic, F. (Fadi); Ortiz, M. (María); Flynt, E. (Erin); Yu, Z. (Zhinuan); Yang, Z. (Zhihong); Rozelle, D. (Dan); Obenauer, J. (John); Trotter, M. (Matthew); Auclair, D. (Daniel); Keats, J.J. (Jonathan J.); Bolli, N. (Niccolo); Fulciniti, M. (Mariateresa); Szalat, R. (Raphael); Moreau, P. (Philippe); Durie, B. (B.); Stewart, A.K. (A. Keith); Goldschmidt, H. (Hartmut); Raab, M.S. (Marc S.); Einsele, H. (Hermann); Sonneveld, P. (Pieter); San-Miguel, J.F. (Jesús F.); Lonial, S. (Sagar); Jackson, G.H. (Graham H.); Anderson, K.C. (K.C.); Avet-Loiseau, H. (Herve); Munshi, N.C. (Nikhil C.); Thakurta, A. (Anjan); Morgan, G.J. (Gareth J.)

Keywords:

Materias Investigacion::Ciencias de la Salud::Oncología

Issue Date:

2019

Publisher:

Springer Science and Business Media LLC

ISSN:

0887-6924

Note:

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

Citation:

Walker, B.A. (Brian A.); Mavrommatis, K. (Konstantinos); Wardell, C.P. (Christopher P.); et al. "A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis". Leukemia. 33, 2019, 159 - 170

Abstract

Patients with newly diagnosed multiple myeloma (NDMM) with high-risk disease are in need of new treatment strategies to improve the outcomes. Multiple clinical, cytogenetic, or gene expression features have been used to identify high-risk patients, each of which has significant weaknesses. Inclusion of molecular features into risk stratification could resolve the current challenges. In a genome-wide analysis of the largest set of molecular and clinical data established to date from NDMM, as part of the Myeloma Genome Project, we have defined DNA drivers of aggressive clinical behavior. Whole-genome and exome data from 1273 NDMM patients identified genetic factors that contribute significantly to progression free survival (PFS) and overall survival (OS) (cumulative R2 = 18.4% and 25.2%, respectively). Integrating DNA drivers and clinical data into a Cox model using 784 patients with ISS, age, PFS, OS, and genomic data, the model has a cumlative R2 of 34.3% for PFS and 46.5% for OS. A high-risk subgroup was defined by recursive partitioning using either a) bi-allelic TP53 inactivation or b) amplification (≥4 copies) of CKS1B (1q21) on the background of International Staging System III, comprising 6.1% of the population (median PFS = 15.4 months; OS = 20.7 months) that was validated in an independent dataset. Double-Hit patients have a dire prognosis despite modern therapies and should be considered for novel therapeutic approaches.

URI:

https://hdl.handle.net/10171/62017

DOI:

10.1038/s41375-018-0196-8

Appears in Collections:

DA - CIMA - Hemato-oncología - Síndromes mieloproliferativos - Artículos de Revista

Files in This Item: